Suppr超能文献

免疫组织化学染色:葡萄胎(HM)恶性转化的预后标志物。

Immunohistochemical Staining: Prognostic Marker of Malignant Transformation of Hydatidiform Mole (HM).

作者信息

Chandran Jyoti Ramesh, Vijaykumar Bindu, Aravindan K P, Rajeevan V, Shammy S

机构信息

Department of Obstetrics and Gynaecology, Government Medical College, Kozhikode, Kerala 673008 India.

Department of Pathology, Govt Medical College Kozhikode, Kozhikode, India.

出版信息

J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):365-370. doi: 10.1007/s13224-024-02002-7. Epub 2024 Jul 23.

Abstract

BACKGROUND

The Gestational Trophoblastic Disease is a spectrum ranging from benign Hydatidiform mole to choriocarcinoma and is generally accompanied by a good prognosis. However, invasive behavior of the tissues in 10-20% of patients may lead to malignant transformation and metastasis. Early detection will be associated with less economic burden on the health system, and higher rates of favorable pregnancy outcomes in women with limited fertility window. Moreover, timely diagnosis may facilitate the appropriate recommendation of prophylactic chemotherapy in the high-risk group of GTN1. Therefore there is a need to find a predictive biomarker for diagnosis of the disease progression. Some Immunohistological (IHC) markers of prognostic significance are: p53, EGFR, HER2 NM23. This study tries to find association of these IHC markers for progression to GTN.

OBJECTIVES

To find prognostic markers of malignant transformation of hydatidiform mole (HM);And to find the outcome of Hydatiform moles in the cohort.

MATERIAL & METHODS: We followed up a cohort of 30-women following evacuation of molar pregnancy on post molar follow up from Jan 2016 to Dec 2020. The IHC of the molar tissues obtained from these patients were evaluated for expression of p53, EGFR, HER2, and Nm23. They were prospectively followed with beta hCG as marker for development of GTN as routine till beta hCG showed normal/Abnormal regression. Those who developed GTN were scored using Figo Prognostic score and given chemotherapy as per protocol.

RESULTS

27 cases of HM were studied.19 were CHM and 8 were PM. 3 patient's IHC could not be done due to inadequate tissue. Age of women ranged from 18-40 years. P53 expression is seen more on surface trophoblast as compared to synchiotrpoblst = 0.02 in patients who developed GTN Grade 3. EGFR - Immunostaining : Minimal staining of synchio and cytotrophoblast in patients with GTN grade 1 ( = 0.10). Her 2 strong membrane positivity for extravillous trophoblasts in contrast to weak reaction on surface trophoblasts grade 2 ( = 0.05). NM23 Increased staining in those with normal beta hCG regression grade 4 ( < 0.0001) those who did not develop GTN, Five patients developed GTN on follow up. 4 were stage 1 Figo score <6 and 1 case was Stage II Figo score low risk <6. All were given single agent chemotherapy with either Methotrexate or Actinomycin D. All responded to Single agent chemotherapy and went into remission. 3 cases were treated with methotrexate (1 case responded with 2 cycles and 2 with 6 cycles) Actinomycin D (2 cases response with 7 & 14 cycles respectively). None of the patients receiving Methotrexate developed side effects but those 2 patients who received Actinomycin D had vomiting, oral ulcers and alopecia.

CONCLUSION

Overexpression of P53 might be considered a potential biomarker to predict the progression of GTD toward malignancy. Overexpression of NM23 has high sensitivity of molar regression. Hence all molar tissues need to be studied for p53 and NM23 IHC Markers. NM23 has highest negative predictive value.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13224-024-02002-7.

摘要

背景

妊娠滋养细胞疾病是一个范围,从良性葡萄胎到绒毛膜癌,通常预后良好。然而,10%-20%患者的组织侵袭行为可能导致恶性转化和转移。早期检测将减轻卫生系统的经济负担,并提高生育窗口有限的女性获得良好妊娠结局的几率。此外,及时诊断可能有助于在高危GTN1组中适当推荐预防性化疗。因此,需要找到一种预测生物标志物来诊断疾病进展。一些具有预后意义的免疫组织化学(IHC)标志物包括:p53、表皮生长因子受体(EGFR)、人表皮生长因子受体2(HER2)、N-myc下游调节基因2(NM23)。本研究试图找出这些IHC标志物与进展为GTN的关联。

目的

寻找葡萄胎(HM)恶性转化的预后标志物;并找出队列中葡萄胎的结局。

材料与方法

我们对2016年1月至2020年12月行葡萄胎清宫术后的30名女性进行了随访。对这些患者的葡萄胎组织进行IHC检测,评估p53、EGFR、HER2和NM23的表达。前瞻性地以β-人绒毛膜促性腺激素(β-hCG)作为GTN发生的标志物进行常规随访,直到β-hCG显示正常/异常消退。对发生GTN的患者使用国际妇产科联盟(FIGO)预后评分进行评分,并按方案给予化疗。

结果

研究了27例HM。19例为完全性葡萄胎(CHM),8例为部分性葡萄胎(PM)。3例患者因组织不足无法进行IHC检测。女性年龄在18至40岁之间。与合体滋养层相比,p53在表面滋养层的表达在发生3级GTN的患者中更明显(P=0.02)。EGFR免疫染色:1级GTN患者的合体滋养层和细胞滋养层染色最少(P=0.10)。HER2在绒毛外滋养层有强膜阳性,而在2级表面滋养层反应较弱(P=0.05)。NM23在β-hCG正常消退的4级患者中染色增加(P<0.0001),这些患者未发生GTN。5例患者在随访中发生GTN。4例为1期FIGO评分<6分,1例为II期FIGO评分低危<6分。所有患者均接受了甲氨蝶呤或放线菌素D的单药化疗。所有患者对单药化疗均有反应并进入缓解期。3例患者接受甲氨蝶呤治疗(1例2个周期有反应,2例6个周期有反应),2例接受放线菌素D治疗(分别为7个周期和14个周期有反应)。接受甲氨蝶呤治疗的患者均未出现副作用,但接受放线菌素D治疗的2例患者出现呕吐、口腔溃疡和脱发。

结论

p53的过表达可能被认为是预测GTD向恶性进展的潜在生物标志物。NM23的过表达对葡萄胎消退具有高敏感性。因此,所有葡萄胎组织都需要进行p53和NM23 IHC标志物检测。NM23具有最高的阴性预测价值。

补充信息

在线版本包含可在10.1007/s13224-024-02002-7获取的补充材料。 (注:原文中10.1007/s13224-024-02002-7最后的数字7疑似有误,这里按原文翻译)

相似文献

4
First-line chemotherapy in low-risk gestational trophoblastic neoplasia.低危妊娠滋养细胞肿瘤的一线化疗
Cochrane Database Syst Rev. 2016 Jun 9;2016(6):CD007102. doi: 10.1002/14651858.CD007102.pub4.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

4
p53: guardian of the genome and policeman of the oncogenes.p53:基因组守护者与癌基因警察
Cell Cycle. 2007 May 2;6(9):1006-10. doi: 10.4161/cc.6.9.4211. Epub 2007 May 28.
10
p53 mutations in human cancers.人类癌症中的p53基因突变。
Science. 1991 Jul 5;253(5015):49-53. doi: 10.1126/science.1905840.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验